Home > Boards > US OTC > Medical - Drugs >

ViaDerma Inc. (VDRM)

Add VDRM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Clonefan, whatarush12, Cryptocol, Chicagojosh, ResidualRevenue
Search This Board: 
Last Post: 3/20/2018 1:30:40 PM - Followers: 511 - Board type: Free - Posts Today: 19


ViaDerma, Inc.

A Division of ViaDerma, Inc. , A Public Company.

Breakthrough Rapid Delivery of Nutrients and Medicines

ViaDerma, Inc. is a biotechnology licensing company committed to bringing new products quickly to the pharmaceutical industry through innovative research & development. ViaDerma licenses products in fields of medicine ranging from infectious diseases to stem-cell therapy.

About Our Products

Proprietary and Trade Secret Mechanism of Action

ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.

The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.

This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.

The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.

Skin Layer Organization

A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.

The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.

Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.

In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.



Vitastem treats Acne, Burns, Eczema, Infections, Psoriasis and Wounds

We are developing products in the following fields of use;

Topical antibiotics

Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.

  • Estimated Global prevalence rate of all types of bacterial infection including pets: 2 Billion.
    Estimated Global prevalence rate of MRSA: 140 million.
Topical toenail antifungal

Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.

Anti-viral formula

Treats symptoms of Influenza which is a$4B/ year global market: Common

  • Estimated Global prevalence rate of Influenza: 355-1065 million.
    Estimated Global prevalence rate of “Bird Flu”: Very rare, about 500 cases.
    Estimated Global prevalence rate of “Swine Flu”: 1420 million were infected in 2009
Wound care

Diabetic foot wounds.

  • Diabetic foot Ulcers; $1.5B/year global market. 12 million people per year

We are currently in discussions with companies in Australia & New Zealand, India, China, and West Africa.


Contact Details

ViaDerma's global headquarters is located at

4640 Admiralty Way, Ste 500

Marina Del Rey, CA 90292

Phone: 310-496-5744



                             Most Recent News    

Most Recent Filings and Disclosures



Verified by Transfer Agent

Authorized Shares: 750,000,000 a/o November 30, 2017

Outstanding Shares: 467,086,221 a/o November 30, 2017

(Restricted 57,318,332 - Unrestriced 409,767,889) a/o November 30, 2017

Held at DTC: 377,884,255 a/o November 30, 2017

Float: 222,337,825 a/o January 25, 2017

Par Value    0.001


$VDRM COULD BE THE pharmacy stock of the year. This stock could run 30,000% here's why.

1) EXTREMELY OVERSOLD and unknown 
2) ONLY 150 MILLION A\S! Makes it the TINIEST FLOAT VS PRICE out of ALL pharmacy stockso in the whole country!
3) Pharmaceutical stocks have the LARGEST PERCENTAGE GAINS OUT OF ALL STOCKS IN THE MARKET on the big boards or the OTHER. 
4) Unusual sudden MASSIVE increase in volume since 3/7/16 LOOK.
7) After being silent for ages 4 JUICY FILINGS came out in September so something could be up.
8) THEY HAVE A PATENT which big boys have to be eyeing.


THIS IS NOT A REGULAR PENNY STOCK. The LOWEST FLOAT vs price vs ALL PHARMA STOCKS IN THE COUNTRY. BIG BOARD OR OTC LAND. ALL OF THEM. Pharma stocks have the HIGHIGHEST EST percentage gain in big boards or penny stocks




CBD Product launch!!!


Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.

Per 12/7/17 PR:  The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. 

Per 1/23/18 PR:  The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.

The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.


"What is Intellectual Property?"
- A Publication by the World Intellectual Property Organization -

2014 Provisional TBD TBD Is this referenced patent application an expired mmj provisional app from 2014? Otiko hasn't explained what happened here. BIOGENX 87290961 641 - Non-Final Action
2016  Patent App TBD TBD "its proprietary innovative transdermal delivery system" VITASTEM 87227123 681 - Publication/Issue Review Complete
2017 "Cannabis Provisional Patent"
(Incorrect Term)
62466209  Was this filed to replace the expired provisional cannabis app from 2014?      
2017 "enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses" 62433964 Is this related to the Viabecline product developed by the Phillips Company using their patent?      
Business Name Owner Registered Otiko's Role
19772 Trident Lane
Huntington Beach, CA 92646
Garrett Adams NV
First registered 12.14.16
Co-owns BIOGENX Trademark - Percent of BIOGENX business owned is unknown
NOTE: The news of BIOGENX as distributor did not reveal Otiko's ownership role.
Chemo-Pharma, Ltd  TBD No result from search
in Canada, England & India
Coast to Coast Podiatry, Inc.
6648 Reseda Blvd
Reseda, CA 91335
 First Registered 06.14.11
Updated 07.13.16
 Otiko states he is "Minority Owner" in his 12.09.16 Video Interview.
He is the named CEO, CFO, Secretary.  He was also sole director until filing of July 2016.
Sole Director is now his wife, Ekaterina Otiko.  Is Ekaterina the majority owner?
NOTE: The news of Coast to Coast as a distributor did not disclose Otiko's ownership role.

ViaDerma, Inc. will Vigorously Defend the Company's Patents, Product Line and its Shareholders from the Current Complaint Against the Company

May 03, 2017

OTC Disclosure & News Service

- ViaDerma, Inc. will Vigorously Defend the Company's Patents, Product Line and its Shareholders from the Current Complaint Against the Company

ViaDerma, Inc. will Vigorously Defend the Company's Patents, Product Line and its Shareholders from the Current Complaint Against the Company


The Company plans on vigorously defending a lawsuit filed by Steven Keough in South Dakota that it believes was filed to stall the product launch of the Company's FDA Registered Viabecline. The Company is also evaluating its own claims against Keough and intends on filing its own claims against Keough.

LOS ANGELES, CA--(Marketwired - May 03, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company's legal counsel, Austin Legal Group, will be addressing the complaint filed by Steven J. Keogh in South Dakota Federal Court. The complaint alleges issues dating back to 2011 which the Company believes have been addressed, and the Company is evaluating potential counter claims against the plaintiff. The Company has filed provisional patents on several products, and their pending status has already gone through a screening process by the USPTO.

The Company's President, Dr. Christopher Otiko, stated, "The Company's legal counsel will vigorously defend this civil legal action to protect our shareholders and the Company's patent pending product line. The Company is moving ahead with its aggressive growth plans and plans to complete its initial production of Viabecline topical antibiotic by the end of Q2."



3/8/18 -;_ylc=X1MDMTE5Nzc4NDE4NQRfZXgDMQRfeXJpZAM2OWRycTI5ZGEyOWllBGcDZFhWcFpEeHVjejVsTUdSbVpUbGtNUzFoWkRkaUxUTTJZVEl0T0dWbVlpMDVPR1k0TlRCbVpEZzJORGwxZFdsa1BHNXpQbFpFVWswPQ0KBGxhbmcDZW4tVVMEb3JpZ19sYW5nA2VuBG9yaWdfcmVnaW9uA0NBBHBvcwMwBHJlZ2lvbgNVUwRzeW1ib2wDVkRSTQ--?.tsrc=applewf

3/2/18 -

2/26/18 -

2/6/18 -

1/23/18 -

12/7/17 -

11/21/17 - ViaDerma, Inc. is Granted Approval to sell VitaStem(TM) its FDA Registered Topical Antibiotic on and Expands Testing into Major US Hospital Chains to Ramp Up Domestic Sales & Begins Production of New Products

10/19/17 - 
ViaDerma, Inc. Commences Distribution of VitaStem(TM), its FDA Registered Topical Antibiotic, and Looks to Expand its Partnership with Biogenx 

09/08/17 - ViaDerma, Inc. Eyes Deal to Place its Patent Pending MMJ Technology into 400 Canadian Retail Stores and an on-line store via the Web, through its Management, Marketing and Distribution Partner in Canada

08/18/2017 - ViaDerma, Inc. Set to Begin Sales of its FDA Registered Topical Antibiotic in September with Initial Orders from Japan

06/27/2017- Viaderma, Inc Receives National Drug Code (NDC) from the FDA for Prolayed, It's New OTC Drug for Premature Ejaculation For Men

06/12/17 - ViaDerma, Inc. Commences First Manufacturing Run And Will Meet the 2nd Quarter Product Distribution Milestone  

05/15/17 - Viaderma, Inc. Recevies Positive Results On Phase I Testing In Canada With Its Proprietary THC delivery and moves to Phase II Trials and Development Of New Products With Its MMJ Technologies 

05/03/17 - ViaDerma, Inc. Will Vigorously Defend The Company's Patents, Product Line, and its Shareholders from current complaint against the company 

04/19/17 - ViaDerma, Inc. Announces its President, Dr. Christopher Otiko's Abstract was Well Received at the DFCON Conference as the Company Completes Final Testing for its FDA Registered Viabecline for Manufacturing in the Next Several Weeks

04/05/17 - ViaDerma, Inc. Enters the Sexual Dysfunction Market & Files with the Food and Drug Administration (FDA) for a New OTC Drug to Conquer Premature Ejaculation for Men

03/20/17 - ViaDerma Receives Provisional Patent Numbers for Its FDA Registered Viabecline and Cannabis Technologies, and Seeks to Distribute its Products with a Management, Marketing and Distribution Company in Canada to Approved International Cannabis Countries

03/08/17 - ViaDerma, Inc. Hires Product Rollout Expert to Manage Quality Control Labeling, Marketing and Distribution of its Go to Market Product Line Launch

02/15/17 - ViaDerma, Inc. Looks to File Additional Patents & License New Products for its (MMJ) Medical Marijuana Patent Pending Delivery Technology with Licensed Dispensaries

02/08/17 - Dr. Chris Ayo Otiko, President of ViaDerma, Inc., is selected to write an article "Healing Diabetic Ulcers with a New Topical Antibiotic Ointment" for the Journal of Diabetes
Science and Technology, a leading US Publication for Diabetes

02/03/17 - ViaDerma, Inc. Targets Online Sales, Wound Care Centers and Distribution Companies for its Viabecline Product Launch, the First Viabecline Orders Set for Q2-2017,
also  Onychomycosis Clinical Studies Show Significant Results

01/11/17 - ViaDerma, Inc's CEO Files New Patent Application, Signs Two Licensing Deals, Locates Product Manufacturers in the US & Abroad, and Plans to add over 500 Affiliates Selling
Viabecline Through Established Online Distribution Networks in 2017

12/09/16 - Video with Dr. Otiko by Jasyn Blair of Uptick Newswire - Notes

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#35738  Sticky Note Expresso123 03/08/18 07:04:12 AM
#34425  Sticky Note Big News for VDRM!! MegaVerde 02/07/18 11:54:52 AM
#27718  Sticky Note AUGUST 21 2017 INTERIM FINANCIAL REPORT Cryptocol 08/23/17 06:07:32 PM
#13415  Sticky Note EVERYBODY: Get back and stay ON-TOPIC here. The topic IH Geek [Dave] 03/05/17 10:10:04 AM
#36354   Unfortunately, there is nothing at the moment to Jayay222 03/20/18 01:30:40 PM
#36353   I dont think it will, if you had kennyt 335 03/20/18 01:11:14 PM
#36352   Plan on at least another 50% less from why_meil 03/20/18 01:04:40 PM
#36351   Thank you, you made it very very clear, kennyt 335 03/20/18 12:23:09 PM
#36350   There is no argument--that is for the lawyers PhenixBleu 03/20/18 12:05:02 PM
#36347   Looks like our support base is around .01.. whatarush12 03/20/18 10:56:12 AM
#36346   I don't understand, are you suggesting that VDRM's scoobey-do 03/20/18 10:55:15 AM
#36345   Agree, I have more dry powder when the Danorocket 03/20/18 09:58:26 AM
#36344   Lower lows, lower highs, more dilution, 1 year Jayay222 03/20/18 09:52:40 AM
#36343   Place your wagers, folks. The race is about Double Cross 03/20/18 09:49:53 AM
#36342   Wish we knew... Danorocket 03/20/18 09:47:42 AM
#36341   Where's the bottom? Jayay222 03/20/18 09:37:33 AM
#36340   i've made that same statement...fully believe in that Grizzerbear 03/20/18 09:34:42 AM
#36339   ViaDerma's fiscal year-end has always been December 31. PhenixBleu 03/20/18 08:52:05 AM
#36338   I stand corrected thanks for the information. I Danorocket 03/20/18 08:24:39 AM
#36337   Some of you people need to get the sunasuna1 03/20/18 08:16:46 AM
#36336   Yes that's forsure! This board is crazy back Danorocket 03/20/18 08:05:14 AM
#36335   Right-on! You nailed it. SchlumpyStock-Picker 03/19/18 11:07:37 PM
#36334   Makes no logical sense..... ddtburg 03/19/18 07:42:14 PM
#36332   Google Trademark vs Patent. Cleared things up quite kennyt 335 03/19/18 03:50:01 PM
#36331   the point is to post the same thing dlr 03/19/18 02:46:26 PM
#36330   The constant debating the dismissed lawsuit has produced SchlumpyStock-Picker 03/19/18 02:42:59 PM
#36329   Good DD. Make sure to post your answers Here Today 03/19/18 02:40:14 PM
#36328   Your argument is based on Keough's argument which SchlumpyStock-Picker 03/19/18 02:37:57 PM
#36327   Attachment 4 of Line Item 57 is the PhenixBleu 03/19/18 02:16:04 PM
#36326   What proof do you have that Otiko worked SchlumpyStock-Picker 03/19/18 02:05:08 PM
#36323   Yessir l know, just wanting everyone who thinks kennyt 335 03/19/18 12:12:51 PM
#36322   The President of Kasten, Inc. is James Cahill. PhenixBleu 03/19/18 12:11:55 PM
#36321   The dictionary definition answered that question. Spaden 03/19/18 12:01:47 PM
#36320   Why in the world would an outstanding IP kennyt 335 03/19/18 11:53:09 AM
#36319   Takes the working from home to a new level. Budman33 03/19/18 11:37:40 AM
#36316   Steven Keough also uses his girlfriend name as Spaden 03/19/18 10:37:56 AM
#36315  Restored Kasten has manufacturing facilites in Connecticut and California. PhenixBleu 03/19/18 10:30:36 AM
#36314   VDRM share holders burst in to laughter eshety 03/19/18 10:04:18 AM
#36313   lol lol salesleader 03/19/18 09:41:50 AM
#36312   No Surprise. I always thought Keough was just SchlumpyStock-Picker 03/19/18 09:27:41 AM
#36311   I was in Sioux Falls this weekend and Spaden 03/19/18 08:56:42 AM
#36310   This will be huge for the cannabis/CBD market... Here Today 03/19/18 07:54:36 AM
#36309   i believe in about 6 months it will eshety 03/18/18 10:55:34 PM
#36306   LOL!! $VDRM is golden! Screaming buy whatarush12 03/18/18 09:29:25 PM
#36286   THIS IS MY FINAL POST HERE AT VDRM,I Tom Trady 03/18/18 01:45:28 PM
#36283   I agree 100% with you. VDRM is scoobey-do 03/18/18 08:34:23 AM
#36282   VDRM will publish fins when they're ready to sunasuna1 03/18/18 07:47:09 AM
#36281   Afterall it is a penny stock it needs eshety 03/17/18 10:39:53 PM
#36280   He was found not guilty on ALL counts Grizzerbear 03/17/18 07:57:54 PM
#36277   Of course it's not b.s. Google Otiko and PhenixBleu 03/17/18 05:19:34 PM
#36274   That is a clever but nevertheless piece of kennyt 335 03/17/18 03:01:51 PM
#36273   Perfect statement ZW... Hope Otiko is not like kennyt 335 03/17/18 02:58:01 PM
#36272   The ongoing Josten Theney copyright infringment case IS PhenixBleu 03/17/18 02:36:10 PM
#36271   We are pretty much there on share price zombywolf 03/17/18 02:20:03 PM